1
|
Enriori PJ, Chen W, Garcia-Rudaz MC, Grayson BE, Evans AE, Comstock SM, Gebhardt U, Müller HL, Reinehr T, Henry BA, Brown RD, Bruce CR, Simonds SE, Litwak SA, McGee SL, Luquet S, Martinez S, Jastroch M, Tschöp MH, Watt MJ, Clarke IJ, Roth CL, Grove KL, Cowley MA. α-Melanocyte stimulating hormone promotes muscle glucose uptake via melanocortin 5 receptors. Mol Metab 2016; 5:807-822. [PMID: 27688995 PMCID: PMC5034615 DOI: 10.1016/j.molmet.2016.07.009] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/29/2016] [Revised: 07/26/2016] [Accepted: 07/28/2016] [Indexed: 01/21/2023] Open
Abstract
Objective Central melanocortin pathways are well-established regulators of energy balance. However, scant data exist about the role of systemic melanocortin peptides. We set out to determine if peripheral α-melanocyte stimulating hormone (α-MSH) plays a role in glucose homeostasis and tested the hypothesis that the pituitary is able to sense a physiological increase in circulating glucose and responds by secreting α-MSH. Methods We established glucose-stimulated α-MSH secretion using humans, non-human primates, and mouse models. Continuous α-MSH infusions were performed during glucose tolerance tests and hyperinsulinemic-euglycemic clamps to evaluate the systemic effect of α-MSH in glucose regulation. Complementary ex vivo and in vitro techniques were employed to delineate the direct action of α-MSH via the melanocortin 5 receptor (MC5R)–PKA axis in skeletal muscles. Combined treatment of non-selective/selective phosphodiesterase inhibitor and α-MSH was adopted to restore glucose tolerance in obese mice. Results Here we demonstrate that pituitary secretion of α-MSH is increased by glucose. Peripheral α-MSH increases temperature in skeletal muscles, acts directly on soleus and gastrocnemius muscles to significantly increase glucose uptake, and enhances whole-body glucose clearance via the activation of muscle MC5R and protein kinase A. These actions are absent in obese mice, accompanied by a blunting of α-MSH-induced cAMP levels in skeletal muscles of obese mice. Both selective and non-selective phosphodiesterase inhibition restores α-MSH induced skeletal muscle glucose uptake and improves glucose disposal in obese mice. Conclusion These data describe a novel endocrine circuit that modulates glucose homeostasis by pituitary α-MSH, which increases muscle glucose uptake and thermogenesis through the activation of a MC5R-PKA-pathway, which is disrupted in obesity. Glucose stimulates α-MSH release from the pituitary. Systemic α-MSH drives glucose disposal and thermogenesis in skeletal muscles. α-MSH acts on MC5R expressed on skeletal muscles and activate cAMP-PKA pathway. The combined treatment of nonselective or selective PDE 4 inhibitor and α-MSH ameliorates glucose intolerance in obese mice.
Collapse
Affiliation(s)
- Pablo J Enriori
- Biomedical Discovery Institute/Department of Physiology, Monash University, Vic, Australia
| | - Weiyi Chen
- Biomedical Discovery Institute/Department of Physiology, Monash University, Vic, Australia
| | - Maria C Garcia-Rudaz
- Biomedical Discovery Institute/Department of Physiology, Monash University, Vic, Australia
| | | | - Anne E Evans
- Division Neuroscience, Oregon Health and Science University, Oregon, USA
| | - Sarah M Comstock
- Division Neuroscience, Oregon Health and Science University, Oregon, USA
| | - Ursel Gebhardt
- Department of Pediatrics, Vestische Children Hospital Datteln, University of Witten/Herdecke, Germany
| | - Hermann L Müller
- Department of Pediatrics, Vestische Children Hospital Datteln, University of Witten/Herdecke, Germany
| | - Thomas Reinehr
- Department of Pediatrics, Klinikum Oldenburg GmbH, Germany
| | - Belinda A Henry
- Biomedical Discovery Institute/Department of Physiology, Monash University, Vic, Australia
| | - Russell D Brown
- Biomedical Discovery Institute/Department of Physiology, Monash University, Vic, Australia
| | - Clinton R Bruce
- Biomedical Discovery Institute/Department of Physiology, Monash University, Vic, Australia
| | - Stephanie E Simonds
- Biomedical Discovery Institute/Department of Physiology, Monash University, Vic, Australia
| | - Sara A Litwak
- Biomedical Discovery Institute/Department of Physiology, Monash University, Vic, Australia
| | - Sean L McGee
- Metabolic Research Unit, School of Medicine, Deakin University, Vic, Australia
| | - Serge Luquet
- Univ Paris Diderot, Sorbonne Paris Cité, Unité de Biologie Fonctionnelle et Adaptative, CNRS UMR 8251, F-75205 Paris, France
| | - Sarah Martinez
- Univ Paris Diderot, Sorbonne Paris Cité, Unité de Biologie Fonctionnelle et Adaptative, CNRS UMR 8251, F-75205 Paris, France
| | - Martin Jastroch
- Institute for Diabetes and Obesity, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg & Division of Metabolic Diseases, Technische Universität, München, Germany
| | - Matthias H Tschöp
- Institute for Diabetes and Obesity, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg & Division of Metabolic Diseases, Technische Universität, München, Germany
| | - Matthew J Watt
- Biomedical Discovery Institute/Department of Physiology, Monash University, Vic, Australia
| | - Iain J Clarke
- Biomedical Discovery Institute/Department of Physiology, Monash University, Vic, Australia
| | - Christian L Roth
- Division of Endocrinology, Seattle Children's Hospital Research Institute, WA, USA
| | - Kevin L Grove
- Division Neuroscience, Oregon Health and Science University, Oregon, USA
| | - Michael A Cowley
- Biomedical Discovery Institute/Department of Physiology, Monash University, Vic, Australia.
| |
Collapse
|